Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 5Terminated 3Completed 3Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Gynecologic 2Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 115Squamous Cell Carcinoma of Head and Neck 61Triple Negative Breast Neoplasms 57Melanoma 54Lung Neoplasms 49Neoplasm Metastasis 48Breast Neoplasms 41Neoplasms 36Colorectal Neoplasms 35Head and Neck Neoplasms 25Endometrial Neoplasms 25Carcinoma, Renal Cell 24Uterine Cervical Neoplasms 21Stomach Neoplasms 21Ovarian Neoplasms 21Carcinoma, Transitional Cell 21Urinary Bladder Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 18Esophageal Neoplasms 16Recurrence 15Carcinoma, Hepatocellular 14Pancreatic Neoplasms 13Sarcoma 12Carcinoma, Squamous Cell 12Glioblastoma 11Esophageal Squamous Cell Carcinoma 11Carcinoma 11Prostatic Neoplasms 10Brain Neoplasms 10Carcinoma, Merkel Cell 9

Interventions

Pemetrexed 6pembrolizumab 5Magnetic Resonance Spectroscopy 5Carboplatin 5Specimen Handling 4Mastectomy, Segmental 4Cisplatin 4Bevacizumab 4durvalumab 2Platinum 2Biopsy 2tislelizumab 1osimertinib 1methyl-4-fluoro-4-deoxyglucose 1methoxyamine 1fludarabine phosphate 1devimistat 1dehydroftorafur 1defactinib 1dapagliflozin 1capmatinib 1aflutinib 1Standard of Care 1Smoking Devices 1Radiotherapy 1Radiation 1RO5126766 1Practice Guidelines as Topic 1Observation 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Adenocarcinoma of Lung × pembrolizumab × Clear all
NCT05797168 2026-06-03

FONTANA

AstraZeneca

Phase 1/2 Recruiting
506 enrolled
GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04339218 2026-01-30

CRYOMUNE

Institut Bergonié

Phase 3 Recruiting
214 enrolled
Thoracic

Adenocarcinoma of Lung

NCT05887492 2025-11-18

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Tango Therapeutics, Inc.

Phase 1/2 Recruiting
126 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05266846 2024-05-30

BEYOND

Hunan Province Tumor Hospital

Phase 2 Recruiting
78 enrolled
Thoracic

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡